Related references
Note: Only part of the references are listed.Intratumour variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer
Jan Nyrop Jakobsen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer
Tobias J. Grob et al.
LUNG CANCER (2013)
Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non-Small-Cell Lung Cancer
Hua Bai et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker et al.
LANCET ONCOLOGY (2012)
Comparison of p53 and Epidermal Growth Factor Receptor Gene Status Between Primary Tumors and Lymph Node Metastases in Non-Small Cell Lung Cancers
Yih-Leong Chang et al.
ANNALS OF SURGICAL ONCOLOGY (2011)
Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy
Chuangzhou Rao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2010)
Differential Expression of Biomarkers in Primary Non-small Cell Lung Cancer and Metastatic Sites
Carlos Gomez-Roca et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platinum-Based Chemotherapy in Lung Cancer Affects the Expression of Certain Biomarkers Including ERCC1
Judit Papay et al.
PATHOLOGY & ONCOLOGY RESEARCH (2009)
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
A. Kalikaki et al.
BRITISH JOURNAL OF CANCER (2008)
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib
Kazuya Taniguchi et al.
CANCER SCIENCE (2008)
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Enriclueta Felip et al.
CLINICAL CANCER RESEARCH (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Cetuximab for the treatment of colorectal cancer
Derek J. Jonker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer
L. Taillade et al.
ANNALS OF ONCOLOGY (2007)
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors
A Italiano et al.
ANNALS OF ONCOLOGY (2006)
HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy
K Junker et al.
LUNG CANCER (2005)
Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare
T De Pas et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer
AP Meert et al.
LUNG CANCER (2004)
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors
AW Burgess et al.
MOLECULAR CELL (2003)
Share Paper
